Key Investor Signals
Co-founder helped build EIT before its Johnson & Johnson acquisition
Co-founder Nancy Lamerigts was VP of Marketing and Research at EIT, the 3D-printed spinal implant company acquired by Johnson & Johnson in 2018.
Patented Y- and U-cassettes target painful neuromas
Atraxon’s patented biodegradable cassettes guide regenerating axons into an autograft to prevent or treat painful neuromas.
Moved the Y-Cassette into in-vivo validation
Atraxon announced that its biodegradable Y-Cassette entered an approved in-vivo validation study to assess nerve regeneration and neuroma prevention.
Team
Nancy Lamerigts
Co-founder
- Served as VP of Marketing and Research at spinal implant developer EIT, which Johnson & Johnson acquired in 2018.
- Co-founded InSpine in 2005, working on research, marketing and communication for surgical-device development.
- Holds MD and PhD qualifications and has focused on spine since 2005, combining medical training with device-industry experience.
Product
Atraxon is developing biodegradable Y- and U-cassette implants for surgical treatment and prevention of painful neuromas. The devices guide regenerating axons into an autograft and are designed for small or large peripheral nerves after trauma, amputation or surgical injury.
Surgical treatment of neuromas
For an established neuroma, the cassette is designed to redirect regenerating axons into autograft tissue, providing a structured pathway instead of leaving the nerve end exposed to disorganized regrowth.
Prevention during nerve management
The same cassette concept is intended for freshly transected nerves after trauma, surgery or amputation, guiding regenerating axons into graft tissue before a painful neuroma forms.
Low-complexity surgical approach
Atraxon’s biodegradable Y- and U-cassettes are designed for different nerve sizes and anatomical locations, with a surgical workflow intended to avoid complex microsurgical reconstruction.
Market Overview
Peripheral nerve injury creates a recurring surgical need across trauma, reconstruction and amputation. Neuromas are a common complication after nerve transection: meta-analyses report symptomatic neuromas in 15% of lower-extremity amputees and 22% of upper-extremity amputees across major patient groups.
The wider nerve-repair and regeneration market is already a multi-billion-dollar category spanning nerve grafting, biomaterials and neuromodulation devices. Industry estimates put global revenue at $11.4 billion in 2025, while U.S. claims data show meaningful spending around surgically managed nerve injuries.
Estimated worldwide nerve repair and regeneration market revenue in 2025.
Pooled symptomatic neuroma prevalence after upper-extremity amputation.
Pooled symptomatic neuroma prevalence after lower-extremity amputation.
Average Medicaid insurer payments within 30 days after surgically treated upper-extremity nerve injury.
Comparable Outcomes
Polyganics
Polyganics developed NEUROCAP, a bioresorbable nerve-capping implant for symptomatic end-neuromas, and other peripheral nerve repair devices. NEUROCAP received FDA clearance in 2016; Collagen Matrix acquired Polyganics in 2022, adding its bioresorbable implant portfolio.
BioCircuit Technologies
BioCircuit Technologies developed NerveTape, a sutureless device for connecting and protecting transected peripheral nerves. Axogen agreed to acquire BioCircuit Technologies for $200 million in cash in September 2026, with closing expected in the fourth quarter.
Interested in More Startups Like Atraxon Biotech?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.